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Background: Recent studies have demonstrated that a coding SNP (rs6967330, Cys529/Tyr) in
cadherin-related family member 3 (CDHR3), which was previously associated with wheezing illness and
hospitalizations in infancy, could support efficient human rhinovirus C (RV-C) entry and replication.
Here, we sought to examine the genetic contribution of this variant to the development of adult asthma.
Methods: We performed a candidate gene caseecontrol association study of 2 independent Japanese
populations (a total of 3366 adults). The odds ratios (ORs) for association of the A allele at rs6967330
with adult asthma were calculated according to age at onset of asthma. In addition, the effect of the
CDHR3 genotype on the development of specific asthma phenotypes was examined.
Results: The A allele was associated with asthma (OR ¼ 1.56; ManteleHaenszel p ¼ 0.0040) when the
analysis was limited to patients with early-onset adult asthma. In addition, when the analysis was
limited to atopic individuals, a stronger association of the CDHR3 variant with early-onset asthma was
found, and interaction of the CDHR3 genotype with atopy was demonstrated. Finally, a significant as-
sociation of this variant was specifically found with a phenotype of asthma characterized by atopy, early-
onset, and lower lung function.
Conclusions: Our study supports the concept that the CDHR3 variant is an important susceptibility factor
for severe adult asthma in individuals who develop the disease in early life. The interaction between the
CDHR3 variant and atopy indicates that genetic predisposition to early respiratory viral infection is
combined with atopy in promoting asthma.
Copyright © 2017, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Asthma is a complex and heterogeneous disease with variable
clinical expression over the lifespan.1 This variable clinicalMedicine, Division of Clinical
a, 1-1-1 Tennodai, Tsukuba,
asuko).
ety of Allergology.
rgology. Production and hosting by Elseexpression encompasses different clinical phenotypes and molec-
ular endotypes depending on the age at onset, presence of allergies,
frequency of exacerbations, and nature of the underlying airway
inflammation.2 Given such phenotypic heterogeneity, selecting
more homogeneous phenotypes for genetic association study could
lead to identification of novel genetic factors for asthma, eventually
allowing us to describe each patient by a distinctive biological
mechanism or endotype and ultimately enhancing our ability to
treat this complex syndrome effectively. On the basis of this
concept, by limiting patients to those with specific phenotypes, wevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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types of asthma, including HAS23 and HCG22.4
A recent genome-wide association study (GWAS) of Danish
children with asthma focused on a specific asthma phenotype
characterized by recurrent episodes of severe exacerbations
requiring hospitalization between 2 and 6 years of age.5 Despite the
relatively smaller sample size than those of other asthma GWASs,
this GWAS of recurrent asthma exacerbations in childhood identi-
fied 1 novel susceptibility locus at the CDHR3 gene. CDHR3 is a
transmembrane protein that is highly expressed in the human lung
and airway epithelium.6,7 It belongs to the cadherin family of pro-
teins, which are involved in homologous cell adhesion and several
cellular processes including epithelial polarity and differentiation.8
The most strongly associated variant at this locus was a non-
synonymous SNP (rs6967330) that results in an amino acid change
in an interdomain region of the protein (Cys529/Tyr).9 Intro-
duction of the risk variant at rs6967330 by means of transfection
resulted in 10-fold increased human rhinovirus C (RV-C) binding
and progeny yield as compared with the nonrisk variant, providing
strong evidence that CDHR3 is an RV-C receptor and that the
asthma association signal with this functional variant in the CDHR3
gene might result from increased susceptibility to RV-C infections.
HRV-induced wheezing illnesses in early life are a significant
risk factor for subsequent development of asthma.10 RV-C has also
been reported to be the most common viral trigger of severe
asthma exacerbations in children and associated with both severer
disease and higher rates of hospital readmissions than are other
viral respiratory tract infections.11e13 Furthermore, HRV seems to be
more prevalent in the airways of adolescents and young adults with
asthma and a high degree of aeroallergen IgE sensitization than in
controls. The presence of HRV was related to systemic eosinophilic
inflammation despite ongoing treatment with inhaled corticoste-
roids.14 In this hypothesis-driven study, therefore, we used a
candidate gene caseecontrol approach to examine the genetic
contribution of the CDHR3 variant (Cys529/Tyr) in Japanese pa-
tients with adult asthma, specifically focusing on early-onset adult
asthma, and to identify the specific phenotypes of adult asthma
associated with increased susceptibility to RV-C infection.
Methods
Subjects
To determine the effect of the CDHR3 variant (Cys529/Tyr), we
studied 2 Japanese adult asthma populations: (1) the “Tsukuba
cohort,” comprising 967 healthy adults who visited the Tsukuba
Medical Center for an annual health checkup and 814 asthmatic
patients from the Tsukuba University Hospital and its affiliated
hospitals,3,15 and (2) the “Hokkaido cohort,” comprising 994
healthy adults and 591 asthmatic patients from the Hokkaido
University Hospital and its affiliated hospitals.15e17 These pop-
ulations were recruited for a caseecontrol genetic association study
of asthma and atopy in Japan.18
Patients were considered asthmatic on the basis of the presence
of recurrent episodes of 2 or more of the 3 symptoms (coughing,
wheezing, and dyspnea) associated with demonstrable reversible
airflow obstruction and/or increased airway responsiveness to
methacholine, as previously described.19 The data for age at onset of
asthma were self-reported. To judge the age at onset of asthma as
accurately as possible, patients were asked about episodes of dys-
pnea, wheezing, or cough they had experienced during childhood
and puberty. In cases of uncertainty, the time of the earliest res-
piratory symptoms was designated as the age at onset of asthma
symptoms.19 The healthy adults in both populations had never been
diagnosed as having asthma. Atopy was assessed by measurementof specific IgE responsiveness to 14 common inhaled allergens
including Dermatophagoides farinae, grass pollens, animal dander,
and molds. We defined atopy as a positive response to at least 1 of
the 14 allergens.17
Ethics statement
This study was approved by the Human Genome Analysis and
Epidemiology Research Ethics Committee of the University of
Tsukuba and by the Human Genome/Gene Analysis Research Ethics
Review Committees of the Tsukuba Medical Center, RIKEN, and the
Hokkaido University School of Medicine. Written informed consent
was obtained from each participant before the investigation in
accordance with the principles of the Declaration of Helsinki.
Genotyping
Genomic DNA was extracted from whole blood by use of an
automated DNA extraction system (QuickGene-610L; Fuji film,
Tokyo, Japan). In the Tsukuba cohort, 243 patients with asthma and
967 nonasthmatic, non-COPD controls underwent GWAS geno-
typing.3 For those individuals without GWAS genotyping, geno-
types for rs6967330 were defined using the TaqMan allele-specific
amplification method (Applied Biosystems, Foster City, CA, USA), as
described previously.20
Statistical analysis
A polymorphism in rs6967330, coding SNP (G/A), converts
residue cysteine to tyrosine at position 529 (Cys529/Tyr). The
odds ratios (ORs) for association of the A allele with adult asthma
were calculated according to the age of disease onset in the 2 in-
dependent Japanese populations. The ManteleHaenszel method
was used to estimate the pooled OR across the populations,
assuming a fixed effects model. One-sided p values of less than 0.05
were judged to be significant to test whether the OR of the CDHR3
variant (Cys529/Tyr) for asthma is significantly greater than 1.
Allergic sensitizations and viral respiratory infections have long
been recognized as two of the most important risk factors for ex-
acerbations of asthma; the combination of allergic sensitization
and viral illnesses greatly increases the risk of asthma exacerbation
and hospitalization.21 We therefore examined the effect of the
CDHR3 variant on early-onset adult asthma in the presence of
atopy. We also examined the interaction of the CDHR3 genotype
and atopy by entering the interaction term of ‘atopy * CDHR3 ge-
notype’ into a multiple logistic regression model.
Analyzing risk factors for asthma by using an overall asthma
population may be misleading and thus emphasizes the impor-
tance of careful asthma phenotyping in epidemiology studies,
which will have important implications for understanding the
pathogenesis of asthma. We therefore searched for phenoty-
peegenotype correlations; we examined the effect of the CDHR3
genotype on the development of previously identified clusters of
adult asthma by using multinomial logistic regression analysis. In
our previous study, 2-step cluster analysis of 880 Japanese adult
asthma patients identified 6 phenotypes using 8 variables: age, sex,
age at onset of the disease, smoking status, total serum IgE, %FEV1,
FEV1/FVC, and specific IgE responsiveness to common inhaled al-
lergens.17 The 6 phenotypes were cluster A: older age at onset, no
airflow obstruction; cluster B: childhood onset, normal-to-mild
airflow obstruction; cluster C: childhood onset, the longest dis-
ease duration, and moderate-to-severe airflow obstruction; cluster
D: older age at onset, severe airflow obstruction; cluster E: middle
age at onset, no airflow obstruction; and cluster F: older age at
onset, mild-to-moderate airflow obstruction. The 2 strongest
Table 1
Characteristics of the study populations.
Tsukuba cohort Hokkaido cohort
Healthy controls Asthmatic patients Healthy controls Asthmatic patients
Number 967 814 994 591
Sex (female, %) 526 (54.4) 466 (57.2) 447 (45.0) 342 (57.9)
Age, y (range) 50.0 (27e74) 56.9 (19e100) 45.0 (18e84) 52.0 (18e84)
Age at asthma onset (range) 40.7 (0e88) 37.2 (0e80)
Smoking pack-year (%)
0 607 (62.8) 514 (65.4) 356 (51.6) 325 (57.8)
0e10 127 (13.1) 93 (11.8) 61 (8.8) 95 (16.9)
>10 233 (24.1) 179 (22.8) 273 (39.6) 142 (25.3)
yAtopy (%) 541 (55.9) 397 (70.9) 517 (52.2) 320 (54.9)
FEV1 %pred. (%, SD) 85.6 (22.5) 88.7 (27.3)
FEV1/FVC (%, SD) 71.2 (12.2) 68.4 (13.2)
In the Tsukuba cohort, information on smoking and atopy was missing in 28 and 254 patients with asthma, respectively. In the Hokkaido cohort, information on smoking and
atopy was missing in 29 and 8 patients with asthma, respectively. In the Tsukuba and Hokkaido cohorts, information on FEV1 was missing in 229 and 47 patients with asthma,
respectively. In the Hokkaido cohort, information on smoking and atopy was missing in 643 and 3 controls, respectively.
y Atopy was defined as the presence of specific IgE Ab in at least 1 of 14 common inhaled allergens.
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at onset of asthma and %FEV1. Using these 2 variables, we devel-
oped a CART model, which we used to determine the cluster for
each patient with adult asthma in the current study. We used 1082
patients with adult asthma for whom data on %FEV1 were available
and who were successfully assigned to a particular asthma cluster
(542 in the Tsukuba cohort and 540 in the Hokkaido cohort), and
1961 healthy adults (967 in the Tsukuba cohort and 994 in the
Hokkaido cohort) as a reference. We used SPSS (version 22) for the
analyses.
Results
The characteristics of the Tsukuba cohort (N ¼ 967) and of the
Hokkaido cohort (N ¼ 994) are shown in Table 1. The rs6967330 of
the control groups of both cohorts did not deviate from the Har-
dyeWeinberg equilibrium (p > 0.5).
In both the Tsukuba and the Hokkaido cohorts, the greater
number of the A allele at rs6967330, which corresponds to the
CDHR3 variant (Cys529/Tyr), was found in patients with asthma
(OR ¼ 1.52 and 1.61; p ¼ 0.036 and 0.026, respectively) when the
analysis was limited to patients with early-onset adult asthma (age
at onset of the disease, 10 years or younger). In the combined
analysis of the Tsukuba and Hokkaido cohorts, the presence of the A
allele was associated with the development of early-onset asthma
with an OR (ManteleHaenszel p value) of 1.56 (0.0040) (Table 2,
Fig. 1). When the analysis was further limited to individuals with
atopy in the combined population, the stronger association of the
CDHR3 variant with early-onset asthma was found in atopic in-
dividuals (OR for the A allele ¼ 2.02 [1.41e2.88]; p ¼ 0.00015;Table 2
Association of the CDHR3 SNP (rs6967330) with early-onset asthma.
rs6967330 (CDHR3-C529Y) Tsukuba cohort
A G Total p value* OR (95% CI)
All participants
Controls 144 1790 1934 0.036 1.52 (1.00e2.30)
Patients with early-onset asthma
(onset at&10 years)
30 246 276
Total 174 2036 2210
Atopic individuals
Controls 68 1014 1082 0.044 1.66 (0.98e2.80)
Patients with early-onset asthma
(onset at&10 years)
20 180 200
Total 88 1194 1282
*1-sided p values of less than 0.05 were judged to be significant to test if the OR of the ATable 2). The interaction of the CDHR3 genotype with atopy was
demonstrated in the regression analysis by formulating product
variables of the CDHR3 genotype and atopy in the model (p for
interaction ¼ 0.027). In contrast, atopy was not associated with the
CDHR3 variant (OR for the A allele ¼ 0.93 [0.77e1.10]; Man-
teleHaenszel p ¼ 0.41).
When the association of this CDHR3 genotype with specific
asthma phenotypes was evaluated by multinomial logistic regres-
sion analysis according to each of the 6 clusters identified in this
study, significant associations of the variant were found with
cluster C (OR 1.95, p ¼ 0.0037; Table 3), which is characterized by
childhood onset, longest disease duration, and moderate-to-severe
airflow obstruction.
Discussion
In the current study, we have shown the importance of the
functional CDHR3 polymorphism in the pathogenesis of early-onset
asthma beyond racial diversity. Although the replication of previ-
ously published GWAS findings may lack the impact of new dis-
coveries, our finding is still important in its own right, especially
given that recent GWAS of childhood asthma failed to replicate the
genetic effect of CDHR3 in a Dutch population.22 Our meta-analysis
of 2 independent Japanese populations of adult asthma showed
that, compared with wild-type CDHR3, the CDHR3 variant
(Cys529/Tyr, rs6967330) is significantly associated with the
development of early-onset adult asthma. CDHR3 is an epithelial
cell-binding site for HRV-C; the CDHR3 gene variant associatedwith
increased asthma hospitalization risk5 conferred increased airway
epithelial expression of CDHR3 and large increases in HRV-CHokkaido cohort Meta-analysis
A G Total p value* OR (95% CI) p value* OR (95% CI)
180 1808 1988 0.026 1.61 (1.04e2.51) 0.0040 1.56 (1.15e2.11)
26 162 188
206 1970 2176
83 951 1034 0.00026 2.64 (1.61e4.35) 0.00015 2.02 (1.41e2.88)
24 104 128
107 1055 1162
allele for asthma is significantly greater than 1.
Fig. 1. ORs for association between rs6967330 and age at onset of specific subsets of
asthma. We studied 1405 asthma cases and 1961 controls from 2 independent Japa-
nese populations who had accurate information on age of onset of asthma. The OR
(95% CI) and its corresponding ManteleHaenszel p-values for association were plotted
between rs6967330 and age at onset of specific subsets of asthma. The numbers of
asthmatic patients who had the disease at the ages of 10 years or younger, 20 years or
younger, 30 years or younger, 40 years or younger, and 50 years or younger were 232,
310, 495, 690, and 907, respectively. ORs significantly greater than 1 are highlighted
(*p < 0.05, **p < 0.005).
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HRV/CDHR3 pathway as a distinct molecular mechanism or endo-
type underlying early-onset allergic adult asthma.
Clustering of asthma patients based on age at onset and lung
function indicated that the CDHR3 variant may be specifically
responsible for the development of a particular phenotype of
asthma characterized by early onset, atopy, and severer airflow
obstruction. In fact, a study of a high risk birth cohort showed that
among outpatient viral wheezing illnesses in early childhood, those
caused by RV infections were the most significant predictors of
decreased lung function up to the age of 8 years, although whether
low lung function is a cause and/or effect of RV wheezing illnesses
remains to be determined.23 Rhinovirus is also found in the sputum
or pharyngeal swab specimens of asthmatic adults without con-
current symptoms of infection or asthma exacerbation; positivity is
associated with lower lung function and more frequent asthma
symptoms.24 Accordingly, although records on the early life history
of severe wheezing illness and asthma exacerbation were not
available for the patients in our cohort, severewheezing illnesses or
frequent asthma exacerbations related to the CDHR3 variant may
have caused airway injury, thus chronically diminishing lung
function. Our findings in adult populations together with the
original study in a pediatric populationmay, therefore, indicate thatTable 3
Multinomial logistic regression between the CDHR3 SNP (rs6967330) and the asthma clu
Cluster Phenotype CDHR3 genotype p Value Odds rati
(95% CI)
AA/AGy (%) GG (%) Total
Cluster A Late-onset
Mild
Less-atopic
33 (17.5) 156 (82.5) 189 0.58 1.12 (0.7
Cluster B Early-onset
Mild
40 (19.4) 166 (80.6) 206 0.20 1.27 (0.8
Cluster C Early-onset
Moderate-to-severe
28 (26.9) 76 (73.1) 104 3.7  103 1.95 (1.2
Cluster D Late-onset
Severe
25 (22.1) 88 (77.9) 113 0.084 1.50 (0.9
Cluster E Middle-age onset
Female-dominant
28 (13.3) 182 (86.7) 210 0.33 0.81 (0.5
Cluster F Late-onset
Moderate
Less atopic
37 (14.2) 223 (85.8) 260 0.49 0.88 (0.6
y Owing to the low frequency of the homozygote for the A allele, this group was comthe genetic effect of CDHR3 underlies asthma persistence from
childhood to adulthood.
We identified a much stronger effect of the CDHR3 variant in
atopic individuals. RV infections and allergy in early life synergize
to increase the risk of developing asthma,25 which clearly involves
several mechanisms. In a study of human subjects infected with
rhinovirus, an increase in the level of IL-33 was detected in the
bronchoalveolar lavage fluid26; the levels of IL-5 and Il-13 secreted
by both cultured T cells and ILC2s were increased in the superna-
tants of rhinovirus-infected airway epithelial cells. RV-induced
lower airway inflammation also precipitates asthma exacerba-
tions through impaired Th1/IL-10 and augmented Th2 responses.27
By enhancing type-2 inflammation, therefore, repeated severe RV
infections may accelerate the progression toward expression of
persistent aggravation of airway disease in asthma-like manifes-
tations. In addition, allergic airway inflammation in asthma can
impair epithelial barrier function, and in vitro studies have indi-
cated that RV replication is enhanced when the apical cells of well-
differentiated epithelial cell cultures are either damaged or strip-
ped away.28 This could secondarily increase the accessibility of
CDHR3 for RV-C binding in individuals with respiratory allergy. As a
result, RV-C could infect more cells, leading to severer respiratory
illness.29 Finally, a mechanism through which IgE impairs rhino-
virus immunity and underlies asthma exacerbations was also
demonstrated30: the Preventative Omalizumab or Step-Up Therapy
for Fall Exacerbations (PROSE) study compared the effects of initi-
ating omalizumab, ICS boost, or placebo before the fall season in
inner-city children and adolescents with asthma and found that
IFN-a responses to rhinovirus were significantly increased within
the omalizumab-treated group. Therefore, IgE likely plays an
important role in the promotion of rhinovirus infection progression
to exacerbations by generating an inflammatory milieu. Altogether,
thesemechanismsmay underlie our finding of a significant effect of
the interaction between the CDHR3 variant and atopy on the
development of early-onset asthma.
In the current study, the functional CDHR3 genotype was spe-
cifically associated with atopic early-onset asthma with decreased
lung function. On the basis of many studies including the current
one, several endotypes of severe asthma have been described,
including increased susceptibility to viral infections, increased
bacterial colonization, impaired lung development, and enhanced
type-2 inflammation.31 Given such a heterogeneity of severe
asthma, a better understanding of the role of HRV in the patho-
genesis of the disease will pave the way to treating patients on the
basis of these endotypes as indicated by the appropriate biomarkers
or treatable traits corresponding to each individual endotype.sters.
o Sex
(female, %)
Age
(y, range)
Age of asthma
onset (y, SD)
FEV1
%predicted (SD)
Atopy
(n, %)
5e1.66) 120 (63.5) 63.7 (31e84) 54.6 (12.0) 110.5 (14.7) 91 (48.1)
8e1.84) 105 (51.0) 37.5 (18e83) 10.1 (8.4) 91.2 (16.0) 140 (74.5)
4e3.05) 41 (40.2) 43.1 (19e82) 14.9 (10.3) 55.9 (1.19) 78 (83.9)
5e2.38) 63 (56.3) 64.8 (38e84) 50.3 (13.6) 48.7 (10.4) 60 (60.6)
4e1.23) 136 (64.8) 52.5 (21e82) 41.1 (13.8) 105.9 (17.1) 109 (56.2)
1e1.27) 165 (63.7) 62.4 (36e88) 51.7 (11.6) 86.2 (25.0) 118 (55.1)
bined with the heterozygote for these analyses.
J. Kanazawa et al. / Allergology International 66 (2017) 563e567 567Acknowledgements
We thank all the physicians who participated in recruiting the
study participants and collecting the data. We also thank Ms F.
Miyamasu, an associate professor at the Faculty of Medicine, Uni-
versity of Tsukuba, who proofread and commented on this paper.
Ms Takako Nakamura gave technical assistance with DNA extrac-
tion from the clinical samples.
Conflict of interest
NH has received lecture fees from AstraZeneca, Astellas Pharma and Boehringer
Ingelheim. The rest of the authors have no conflict of interest.
Authors' contributions
JK analyzed the data and drafted the manuscript. HM, YY, HY, HI, TSak, and NH
contributed to the design and data analyses and drafted the manuscript. YK, HK, TN,
TSai, EN, SK, MN, TH, and MT were involved in the study conception and data
interpretation. NH supervised the entire research. All authors read and approved the
final manuscript.
References
1. Martinez FD, Vercelli D. Asthma. Lancet 2013;382:1360e72.
2. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular ap-
proaches. Nat Med 2012;18:716e25.
3. Yatagai Y, Sakamoto T, Yamada H, Masuko H, Kaneko Y, Iijima H, et al.
Genomewide association study identifies HAS2 as a novel susceptibility gene
for adult asthma in a Japanese population. Clin Exp Allergy 2014;44:1327e34.
4. Yatagai Y, Hirota T, Sakamoto T, Yamada H, Masuko H, Kaneko Y, et al. Variants
near the HLA complex group 22 gene (HCG22) confer increased susceptibility
to late-onset asthma in Japanese populations. J Allergy Clin Immunol 2016;138.
281e3.e13.
5. Bonnelykke K, Sleiman P, Nielsen K, Kreiner-Moller E, Mercader JM, Belgrave D,
et al. A genome-wide association study identifies CDHR3 as a susceptibility
locus for early childhood asthma with severe exacerbations. Nat Genet
2014;46:51e5.
6. Yanai I, Benjamin H, Shmoish M, Chalifa-Caspi V, Shklar M, Ophir R, et al.
Genome-wide midrange transcription profiles reveal expression level re-
lationships in human tissue specification. Bioinformatics 2005;21:650e9.
7. Ross AJ, Dailey LA, Brighton LE, Devlin RB. Transcriptional profiling of muco-
ciliary differentiation in human airway epithelial cells. Am J Respir Cell Mol Biol
2007;37:169e85.
8. Hulpiau P, van Roy F. Molecular evolution of the cadherin superfamily. Int J
Biochem Cell Biol 2009;41:349e69.
9. Bochkov YA, Watters K, Ashraf S, Griggs TF, Devries MK, Jackson DJ, et al.
Cadherin-related family member 3, a childhood asthma susceptibility gene
product, mediates rhinovirus C binding and replication. Proc Natl Acad Sci U S A
2015;112:5485e90.
10. Jamieson KC, Warner SM, Leigh R, Proud D. Rhinovirus in the pathogenesis and
clinical course of asthma. Chest 2015;148:1508e16.
11. Cox DW, Bizzintino J, Ferrari G, Khoo SK, Zhang G, Whelan S, et al. Human
rhinovirus species C infection in young children with acute wheeze is associ-
ated with increased acute respiratory hospital admissions. Am J Respir Crit Care
Med 2013;188:1358e64.
12. Bizzintino J, Lee WM, Laing IA, Vang F, Pappas T, Zhang G, et al. Association
between human rhinovirus C and severity of acute asthma in children. Eur
Respir J 2011;37:1037e42.13. Miller EK, Khuri-Bulos N, Williams JV, Shehabi AA, Faouri S, Al Jundi I, et al.
Human rhinovirus C associated with wheezing in hospitalised children in the
Middle East. J Clin Virol 2009;46:85e9.
14. €Ohrmalm L, Malinovschi A, Wong M, Levinson P, Janson C, Broliden K, et al.
Presence of rhinovirus in the respiratory tract of adolescents and young adults
with asthma without symptoms of infection. Respir Med 2016;115:1e6.
15. Masuko H, Sakamoto T, Kaneko Y, Iijima H, Naito T, Noguchi E, et al. Lower
FEV1 in non-COPD, nonasthmatic subjects: association with smoking, annual
decline in FEV1, total IgE levels, and TSLP genotypes. Int J Chron Obstruct Pul-
mon Dis 2011;6:181e9.
16. Taniguchi N, Konno S, Hattori T, Isada A, Shimizu K, Shimizu K, et al. The CC16
A38G polymorphism is associated with asymptomatic airway hyper-
responsiveness and development of late-onset asthma. Ann Allergy Asthma
Immunol 2013;111:376e81.
17. Kaneko Y, Masuko H, Sakamoto T, Iijima H, Naito T, Yatagai Y, et al. Asthma
phenotypes in Japanese adults e their associations with the CCL5 and ADRB2
genotypes. Allergol Int 2013;62:113e21.
18. Yatagai Y, Sakamoto T, Masuko H, Kaneko Y, Yamada H, Iijima H, et al. Genome-
Wide Association Study for levels of total serum IgE identifies HLA-C in a
Japanese population. PLoS One 2013;8:e80941.
19. Hizawa N, Yamaguchi E, Konno S, Tanino Y, Jinushi E, Nishimura M.
A functional polymorphism in the RANTES gene promoter is associated with
the development of late-onset asthma. Am J Respir Crit Care Med 2002;166:
686e90.
20. Harada M, Hirota T, Jodo AI, Hitomi Y, Sakashita M, Tsunoda T, et al. Thymic
stromal lymphopoietin gene promoter polymorphisms are associated with
susceptibility to bronchial asthma. Am J Respir Cell Mol Biol 2011;44:787e93.
21. Rakes GP, Arruda E, Ingram JM, Hoover GE, Zambrano JC, Hayden FG, et al.
Rhinovirus and respiratory syncytial virus in wheezing children requiring
emergency care: IgE and eosinophil analyses. Am J Respir Crit Care Med
1999;159:785e90.
22. Nieuwenhuis MA, Siedlinski M, van den Berge M, Granell R, Li X, Niens M, et al.
Combining genomewide association study and lung eQTL analysis provides
evidence for novel genes associated with asthma. Allergy 2016;71:1712e20.
23. Guilbert TW, Singh AM, Danov Z, Evans MD, Jackson DJ, Burton R, et al.
Decreased lung function after preschool wheezing rhinovirus illnesses in
children at risk to develop asthma. J Allergy Clin Immunol 2011;128. 532e8.e1-
10.
24. Harju TH, Leinonen M, Nokso-Koivisto J, Korhonen T, R€aty R, He Q, et al.
Pathogenic bacteria and viruses in induced sputum or pharyngeal secretions of
adults with stable asthma. Thorax 2006;61:579e84.
25. Gavala ML, Bertics PJ, Gern JE. Rhinoviruses, allergic inflammation, and asthma.
Immunol Rev 2011;242:69e90.
26. Jackson DJ, Makrinioti H, Rana BM, Shamji BW, Trujillo-Torralbo MB, Footitt J,
et al. IL-33-dependent type 2 inflammation during rhinovirus-induced asthma
exacerbations in vivo. Am J Respir Crit Care Med 2014;190:1373e82.
27. Message SD, Laza-Stanca V, Mallia P, Parker HL, Zhu J, Kebadze T, et al.
Rhinovirus-induced lower respiratory illness is increased in asthma and
related to virus load and Th1/2 cytokine and IL-10 production. Proc Natl Acad
Sci USA 2008;105:13562e7.
28. Jakiela B, Brockman-Schneider R, Amineva S, Lee WM, Gern JE. Basal cells of
differentiated bronchial epithelium are more susceptible to rhinovirus infec-
tion. Am J Respir Cell Mol Biol 2008;38:517e23.
29. Bochkov YA, Gern JE. Rhinoviruses and their receptors: implications for allergic
disease. Curr Allergy Asthma Rep 2016;16:30.
30. Teach SJ, Gill MA, Togias A, Sorkness CA, Arbes Jr SJ, Calatroni A, et al. Pre-
seasonal treatment with either omalizumab or an inhaled corticosteroid boost
to prevent fall asthma exacerbations. J Allergy Clin Immunol 2015;136:
1476e85.
31. Hizawa N. Clinical approaches towards asthma and chronic obstructive pul-
monary disease based on the heterogeneity of disease pathogenesis. Clin Exp
Allergy 2016;46:678e87.
